Do you offer nivolumab for metastatic HCC in the second line or if sorafenib is intolerable?
Currently, nivolumab is approved as a second line systemic therapy for patients with metastatic HCC with Child-Pugh (CP) A-B7 based on results from CheckMate 040. Would you consider this treatment in patients with appropriate PS but with CP-C?
Community PollStarted
Would you offer Nivolumab for metastatic HCC in patient that is Child Pugh Class C?
39 physicians have voted
Join Mednetto vote and see how they answered.
1 Answer
Mednet MemberInvited Expert
Medical Oncology · Keck School of Medicine of USC
Answered on
Using nivolumab in second line if the patient cannot tolerate sorafenib is appropriate; the regorefanib RESORCE trial had selected patients who tolerated sorafenib at a minimum dose of 400 mg daily for 20 of the 28 days prior to study entry.
The challenge is the child pugh C status of the patient. We do not have safety data in this setting. Safety of Nivolumab in child pugh B 7 and 8 patients will be presented at AASLD in about a week. So far, real world experience indicates good tolerability in ...
Join for free or sign in to see the full answer